251 related articles for article (PubMed ID: 23702781)
1. The CCR6/CCL20 axis mediates Th17 cell migration to the ocular surface in dry eye disease.
Dohlman TH; Chauhan SK; Kodati S; Hua J; Chen Y; Omoto M; Sadrai Z; Dana R
Invest Ophthalmol Vis Sci; 2013 Jun; 54(6):4081-91. PubMed ID: 23702781
[TBL] [Abstract][Full Text] [Related]
2. CCL20 Secretion from the Nucleus Pulposus Improves the Recruitment of CCR6-Expressing Th17 Cells to Degenerated IVD Tissues.
Zhang W; Nie L; Wang Y; Wang XP; Zhao H; Dongol S; Maharjan S; Cheng L
PLoS One; 2013; 8(6):e66286. PubMed ID: 23823618
[TBL] [Abstract][Full Text] [Related]
3. CCL20 inhibition for treating inflammation in ankylosing spondylitis.
Won EJ; Kim HJ; Lee YJ; Kim MJ; Lee HI; Jang HH; Kim SH; Kang JH; Park KJ; Shim SC; Jo S; Kim TH; Kim TJ
Rheumatology (Oxford); 2023 Dec; 62(12):4000-4005. PubMed ID: 37279731
[TBL] [Abstract][Full Text] [Related]
4. CCR6-CCL20 axis as a therapeutic target for autoimmune diseases.
Meitei HT; Jadhav N; Lal G
Autoimmun Rev; 2021 Jul; 20(7):102846. PubMed ID: 33971346
[TBL] [Abstract][Full Text] [Related]
5. The CCL20 and CCR6 axis in psoriasis.
Furue K; Ito T; Tsuji G; Nakahara T; Furue M
Scand J Immunol; 2020 Mar; 91(3):e12846. PubMed ID: 31692008
[TBL] [Abstract][Full Text] [Related]
6. Anti-psoriasis effect of 18β-glycyrrhetinic acid by breaking CCL20/CCR6 axis through its vital active group targeting GUSB/ATF2 signaling.
Wei J; Zhang J; Hu F; Zhang W; Wu Y; Liu B; Lu Y; Li L; Han L; Lu C
Phytomedicine; 2024 Jun; 128():155524. PubMed ID: 38552435
[TBL] [Abstract][Full Text] [Related]
7. CCL20-CCR6 axis modulated traumatic brain injury-induced visual pathologies.
Das M; Tang X; Han JY; Mayilsamy K; Foran E; Biswal MR; Tzekov R; Mohapatra SS; Mohapatra S
J Neuroinflammation; 2019 May; 16(1):115. PubMed ID: 31151410
[TBL] [Abstract][Full Text] [Related]
8. CCL20/CCR6 axis mediates macrophages to promote proliferation and migration of ESCs by blocking autophagic flux in endometriosis.
Tan J; Xu T; Gou Y; Wang H; Liang Z; Cao Y; Wang H; Yu Y; Jiao N; Zhang Z
Stem Cell Res Ther; 2022 Jul; 13(1):294. PubMed ID: 35841069
[TBL] [Abstract][Full Text] [Related]
9. Tumor-derived CCL20 affects B16 melanoma growth in mice.
Martin-Garcia D; Silva-Vilches C; Will R; Enk AH; Lonsdorf AS
J Dermatol Sci; 2020 Jan; 97(1):57-65. PubMed ID: 31883833
[TBL] [Abstract][Full Text] [Related]
10. Neurokinin-1 Receptor Antagonism Ameliorates Dry Eye Disease by Inhibiting Antigen-Presenting Cell Maturation and T Helper 17 Cell Activation.
Yu M; Lee SM; Lee H; Amouzegar A; Nakao T; Chen Y; Dana R
Am J Pathol; 2020 Jan; 190(1):125-133. PubMed ID: 31669306
[TBL] [Abstract][Full Text] [Related]
11. The CCL20-CCR6 Axis in Cancer Progression.
Kadomoto S; Izumi K; Mizokami A
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707869
[TBL] [Abstract][Full Text] [Related]
12. Circulating CCL20: A potential biomarker for active vitiligo together with the number of Th1/17 cells.
Zhang L; Kang Y; Chen S; Wang L; Jiang M; Xiang L
J Dermatol Sci; 2019 Feb; 93(2):92-100. PubMed ID: 30655106
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-17 Receptor E and C-C Motif Chemokine Receptor 10 Identify Heterogeneous T Helper 17 Subsets in a Mouse Dry Eye Disease Model.
Wang J; Gong J; Yang Q; Wang L; Jian Y; Wang P
Am J Pathol; 2022 Feb; 192(2):332-343. PubMed ID: 35144761
[TBL] [Abstract][Full Text] [Related]
14. The CCR6-CCL20 axis in humoral immunity and T-B cell immunobiology.
Lee AYS; Körner H
Immunobiology; 2019 May; 224(3):449-454. PubMed ID: 30772094
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the CCR6-CCL20 axis prevents regulatory T cell recruitment and sensitizes head and neck squamous cell carcinoma to radiation therapy.
Rutihinda C; Haroun R; Saidi NE; Ordoñez JP; Naasri S; Lévesque D; Boisvert FM; Fortier PH; Belzile M; Fradet L; Hubert-Tremblay V; Turgeon GA; Wang CS; Delage P; Rousseau É; Paquette B; Oweida AJ
Cancer Immunol Immunother; 2023 May; 72(5):1089-1102. PubMed ID: 36326893
[TBL] [Abstract][Full Text] [Related]
16. Amino terminal recognition by a CCR6 chemokine receptor antibody blocks CCL20 signaling and IL-17 expression via β-arrestin.
Gómez-Melero S; García-Maceira FI; García-Maceira T; Luna-Guerrero V; Montero-Peñalvo G; Túnez-Fiñana I; Paz-Rojas E
BMC Biotechnol; 2021 Jul; 21(1):41. PubMed ID: 34225700
[TBL] [Abstract][Full Text] [Related]
17. SMAD4 Suppresses Colitis-associated Carcinoma Through Inhibition of CCL20/CCR6-mediated Inflammation.
Hanna DN; Smith PM; Novitskiy SV; Washington MK; Zi J; Weaver CJ; Hamaamen JA; Lewis KB; Zhu J; Yang J; Liu Q; Beauchamp RD; Means AL
Gastroenterology; 2022 Nov; 163(5):1334-1350.e14. PubMed ID: 35863523
[TBL] [Abstract][Full Text] [Related]
18. PPARδ dysregulation of CCL20/CCR6 axis promotes gastric adenocarcinoma carcinogenesis by remodeling gastric tumor microenvironment.
Liu Y; Wei D; Deguchi Y; Xu W; Tian R; Liu F; Xu M; Mao F; Li D; Chen W; Valentin LA; Deguchi E; Yao JC; Shureiqi I; Zuo X
Gastric Cancer; 2023 Nov; 26(6):904-917. PubMed ID: 37572185
[TBL] [Abstract][Full Text] [Related]
19. C-C Motif Ligand 20 (CCL20) and C-C Motif Chemokine Receptor 6 (CCR6) in Human Peripheral Blood Mononuclear Cells: Dysregulated in Ulcerative Colitis and a Potential Role for CCL20 in IL-1β Release.
Skovdahl HK; Damås JK; Granlund AVB; Østvik AE; Doseth B; Bruland T; Mollnes TE; Sandvik AK
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347808
[TBL] [Abstract][Full Text] [Related]
20. A myostatin-CCL20-CCR6 axis regulates Th17 cell recruitment to inflamed joints in experimental arthritis.
Fennen M; Weinhage T; Kracke V; Intemann J; Varga G; Wehmeyer C; Foell D; Korb-Pap A; Pap T; Dankbar B
Sci Rep; 2021 Jul; 11(1):14145. PubMed ID: 34239010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
